Technology | Drug-Eluting Balloons | August 29, 2017

Lutonix 035 Drug Coated Balloon Earns Additional FDA Premarket Approval

Approval provides new option for treatment of patients with dysfunctional AV fistulae to preserve vascular access and help hemodialysis patients extend time between reinterventions

Lutonix 035 Drug Coated Balloon Earns Additional FDA Premarket Approval

August 29, 2017 — C.R. Bard Inc. announced the Lutonix 035 Drug Coated Balloon PTA Catheter (DCB) has been granted premarket approval (PMA) by the U.S. Food and Drug Administration (FDA) for a new indication. With this approval, the device becomes the first and only drug-coated balloon that is FDA-approved as safe and effective in end-stage renal disease (ESRD) patients with stenotic lesions in dialysis arteriovenous (AV) fistulae.

This latest approval adds to the prior FDA indication of the Lutonix 035 for the treatment of superficial femoral artery (SFA) and popliteal artery disease.

The FDA approval was based on the results of the LUTONIX AV Clinical Trial, the first investigational device exemption (IDE) trial using drug-coated balloons in patients with stenotic lesions in AV fistulae. The follow-up results from randomized patients who were treated with the device demonstrated safety comparable to uncoated balloons.

The Lutonix 035 also demonstrated a sustained clinical benefit compared to conventional angioplasty through 12 months:

  • Target lesion primary patency (TLPP) of 71.4 percent at 180 days, with superior results at 210 days (DCB 64.1 percent vs. percutaneous transluminal angioplasty [PTA] 52.5 percent);
  • Fewer reinterventions compared to PTA at 6 months (31.3 percent);
  • Nearly two (2) months more reintervention-free days (217 days vs. 163 days) compared to PTA;
  • Improvement in TLPP through 12 months of 31.2 percent; and
  • Freedom from primary safety event of 95 percent, indicating a consistent safety profile to PTA.

Globally, there are more than 2 million patients undergoing hemodialysis treatments¹ – each therapy session lasting approximately four hours and occurring up to three times per week – in a hospital or dialysis center.² To receive this therapy, many patients depend on an AV fistula³, which is the connection of an artery to a vein created by a vascular surgeon. For these patients, blockages created by repeated access or narrowing of the blood vessel (restenosis) are a common problem and hinder treatment. Some patients require up to eight reinterventions per year to maintain AV fistula function⁴, their lifeline for managing renal disease.

“For patients undergoing hemodialysis for kidney failure – who already spend a significant portion of their time undergoing dialysis and other treatments – repeated reinterventions to maintain AV access can be an added burden, with many patients returning as frequently as every other month,” said Scott O. Trerotola, M.D., Stanley Baum Professor of Radiology, associate chair and chief, interventional radiology, Perelman School of Medicine of the University of Pennsylvania and principal investigator of the LUTONIX AV Clinical Trial. “The Lutonix 035 DCB Catheter provides another option for physicians. It’s intended to offer patients with end-stage renal disease fewer interruptions in treatment and less time undergoing access maintenance, potentially leading to improved patient satisfaction and quality of life.”

The LUTONIX AV Clinical Trial included 285 subjects with lesion locations ranging from AV anastomoses at the wrist to the axillosubclavian junction at the shoulder. The trial design incorporated core laboratory evaluations on all patients, monitoring of all data points, independent Clinical Events Committee (CEC) adjudication and Data and Safety Monitoring Board (DSMB) review.

The two-year study is ongoing with additional endpoints at 18 and 24 months.

For more information: www.crbard.com

 

Read about the first FDA approvals for DCBs "Drug-eluting Balloons Enter the U.S. Market."
 

 

References

1. ESRD Patients in 2013: A Global Perspective – Fresenius Medical Care.

2. A to Z Health Guide: Dialysis – National Kidney Foundation.

3. Vascular Access for Hemodialysis- National Institute of Diabetes and Digestive and Kidney Diseases.

4. New Insights into Dialysis Vascular Access: Impact of Preexisting Arterial and Venous Pathology on AVF and AVG Outcomes – Clinical Journal of the American Society of Nephrology.

Related Content

CorInnova Awarded 2017 InnoSTARS Prize for EpicHeart Soft Robotic Heart Assist Device
News | Artificial Heart| December 11, 2017
CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science competition for its...
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Robocath Receives $1.5 Million in Capital for Advancement of R-One Robotic System
News | Robotic Systems| December 06, 2017
December 6, 2017 — French company Robocath, which designs and develops...
New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

Feature | December 06, 2017 | Dave Fornell
Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magaz
New Tool Predicts Risk of Heart Attack in Older Surgery Patients
News | Cardiac Diagnostics| December 05, 2017
A tool designed to more accurately predict the risk of heart attack in older patients undergoing non-cardiac surgery...
Toshiba Medical Rolls Out Interactive Learning Tools for Ultrasound and Vascular Training
News | Ultrasound Imaging| December 04, 2017
Toshiba Medical, a Canon Group company, introduced new educational tools and interactive learning resources to help...
Philips Azurion Platform Improves Clinical Workflow and Staff Experience Benefits
News | Angiography| December 04, 2017
Philips recently announced the results of a comprehensive, independent, two-year study demonstrating the clinical...
Studies find 15 percent of all heart attack and stroke patients and 9 percent of CABG patients were uninsured before passage of the Affordable Care Act. AHA 2017, #aha2017
News | November 25, 2017
November 25, 2017 — The majority of patients without health insurance who were hospitalized for heart attack, stroke
The Corvia intra-atrial shunt to treat diastolic heart failure.

The Corvia intra-atrial shunt to treat diastolic heart failure.

Feature | Heart Failure| November 25, 2017
November 25, 2017 – Results presented at the 2017 American Heart Association (AHA) Scientific Sessions and published
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init